Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $8 Million Underwritten Public Offering of BiondVax Pharmaceuticals Ltd.

Press Release – New York, NY – December 21, 2022 – Sichenzia Ross Ference LLP today announced that it represented Aegis Capital Corp. as sole book running manager in the $8 Million underwritten public offering of BiondVax Pharmaceuticals, a biotechnology company which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products. The offering consisted of 1,600,000 units and pre-funded units, with each unit consisting of one American Depositary Share (“ADS”) and two warrants, each to purchase one ADS, at a combined purchase price of $5.00 per unit (or $4.999 per pre-funded unit after reducing $0.001 attributable to the exercise price of the pre-funded warrants). The gross proceeds of the offering to the company were approximately $8 million.

The shares were issued pursuant to a Form F-1 registration statement (No. 333-267648) filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on December 15, 2022. The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Darrin Ocasio, Barrett DiPaolo, and associates Matthew Siracusa and Mayank Pradhan.

Author
Recent Posts

Sichenzia Ross Ference Carmel LLP

Sichenzia Ross Ference Carmel LLP is a full service law firm with a nationally recognized corporate, securities and litigation practice that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRFC’s renowned litigation department specializes in defending companies and individuals against all types of securities cases, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations. The litigation team has also brought defamation lawsuits against companies and individuals related to market manipulation. Additionally, it represents individuals and companies in investigations by the Securities and Exchange Commission (SEC) and other regulatory bodies. The litigation team has a robust practice representing brokers and broker-dealers in arbitrations before the Financial Industry Regulatory Authority (FINRA). These arbitrations typically involve claims of unsuitability, churning, unauthorized trading and other allegations of broker misconduct. Finally, SRF has a burgeoning expungement practice, where it represents brokers seeking to have negative and harmful customer complaints removed from their industry records. The firm complements its core practice areas with an established commercial real estate and trusts and estates practice.

Visit SRFC's LinkedIn page

Latest posts by Sichenzia Ross Ference Carmel LLP (see all)

Sichenzia Ross Ference Carmel LLP Represents Aegis Capital Corp. in the $8.2 Million Private Placement of SOBRsafe, Inc. - October 8, 2024
Sichenzia Ross Ference Carmel LLP represents A2Z Cust2Mate Solutions Corp. in $4 Million Registered Direct Offering - October 2, 2024
Sichenzia Ross Ference Carmel LLP represents BriaCell Therapeutics in $5.0 Million Offering - October 2, 2024

Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $8 Million Underwritten Public Offering of BiondVax Pharmaceuticals Ltd.

Related Posts